Peripheral edema: Peripheral edema is a known effect of the class of endothelin receptor antagonists, and it is a clinical consequence of PAH and worsening PAH. In the placebo-controlled studies, the incidence of peripheral edema increased in patients receiving ambrisentan 5 or 10 mg, compared to those receiving placebo. Most edema was mild to moderate [...]

Indications: Ambrisentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization Group 1) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening. PAH is a rare, life-threatening condition characterized by continuous high blood pressure within the arteries of the [...]

Indication: Armodafinil is designed to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome, narcolepsy, and shift work sleep disorder. In obstructive sleep apnea/hypopnea syndrome, armodafinil is indicated as an adjunct to standard therapy for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice, a maximal [...]

Rivastigmine Transdermal System (Exelon Patch) Manufacturer: Novartis Pharmaceuticals Corp, East Hanover, NJ Indication: The rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type and for mild-to-moderate dementia associated with Parkinson’s disease (PD). The dementia of PD is characterized by impairments in executive function, memory retrieval, and attention. Drug Class: [...]